Evaluating the effectiveness of systemic heparin during arteriovenous fistula creation by emulating a target trial.

ABSTRACT: Most of the 800 000 people living with end-stage kidney disease in the United States rely on a functioning vascular access to provide life-sustaining hemodialysis, yet one-third of arteriovenous fistulas experience early failures. Determining the safety and effectiveness of systemic heparin during fistula creation could improve the quality and quantity of life for these vulnerable patients. In this article, a pragmatic randomized trial was emulated to assess the effect of systemic heparin administration (vs none) during radiocephalic arteriovenous fistula creation on early bleeding and thrombosis, using data from 2 international, multicenter, randomized trials performed between 2014 and 2019. Marginal risks were estimated using inverse probability weighted parametric survival analysis and

SUBMITTER: Heindel P 

PROVIDER: S-EPMC12166180 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature